Table 1

Clinical trials designed to investigate PROTAC AR degraders for the treatment of advanced prostate cancer

Drug name	Clinical trial identifier	Location	Disease setting	Phase	Status	Efficacy results^a
Bavdegalutamide (ARV-110)	NCT03888612	US	mCRPC	Phase 1/2	Primary stage completed; study ongoing	46% PSA₅₀ rate and RECIST responses occurred in patients with tumors harboring AR T878X or H875Y mutations. A ≥ 50% decrease in PSA occurred in patients without AR T878X/H875Y mutations⁶.
ARV-766	NCT05067140	US	mPC	Phase 1/2	Ongoing	50% PSA₅₀ rate in patients with AR LBD mutations⁷.
HP518	NCT06155084	China	mCRPC	Phase 1	Ongoing	–
	NCT05252364	Australia	mCRPC	Phase 1	Complete	–
AC176	NCT05673109	China	mCRPC	Phase 1	Terminated	–
	NCT05241613	US	mCRPC	Phase 1	Terminated	–

↵^aListed for phase ≥2 trials for which data are available. AR, androgen receptor; LBD, ligand-binding domain; mCRPC, metastatic castration-resistant prostate cancer; PROTAC, PROteolysis TArgeting Chimera; RECIST, response evaluation criteria in solid tumors; PSA, prostate-specific antigen.